Form 4: Acadia Pharmaceuticals CFO Sells Shares Under 10b5-1 Plan

Mark C. Schneyer, EVP and CFO of Acadia Pharmaceuticals, sold 2,000 shares of common stock at $25 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Mark C. Schneyer, the EVP and CFO of Acadia Pharmaceuticals, reported a transaction involving the company's common stock.
• On May 16, 2025, Schneyer sold 2,000 shares of common stock at a price of $25 per share.
• The sale was executed under a Rule 10b5-1 trading plan adopted on May 30, 2024.
• Following the transaction, Schneyer beneficially owns 62,130 shares of Acadia Pharmaceuticals.
• This total includes 1,357 shares acquired on May 15, 2025, through an employee stock purchase plan.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale under a pre-arranged plan. It doesn't inherently convey positive or negative sentiment.

Positives

• The sale was conducted under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Industry Context

Sales by company executives are a normal part of corporate governance. The use of a 10b5-1 plan suggests the executive is selling shares according to a pre-arranged schedule to avoid any implications of insider trading.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates

Keywords

Acadia Pharmaceuticals, Mark C. Schneyer, CFO, Stock Sale, Form 4, 10b5-1 Trading Plan, Insider Trading, Employee Stock Purchase Plan